Despite the large adoption of modern therapeutic options, like insulin pumps, continuous glucose monitoring (CGM) systems or artificial pancreases, only 21% to 30% of adults living with type 1 diabetes (T1D) achieve a glycated hemoglobin target lower than 7%. This target is recommended by the current Canadian guidelines to reduce the risk of various diabetic … Read more
Type 1 diabetes (T1D) is an autoimmune disease in which the immune system misses its target and destroys the insulin-producing beta cells. Since insulin is a vital hormone, people with T1D must take multiple injections of insulin daily. Actually, insulin isn’t the only hormone affected; there are several other hormones that are either missing or … Read more
Type 1 diabetes (T1D) doesn’t take a break; it is there 24 hours a day, 7 days a week, 365 days a year. People with T1D are therefore particularly well placed to understand the real physical, mental and social impacts of the disease and its associated treatments. However, their voice is barely valued in the … Read more
Written August 2020, updated February 2023 People with type 1 diabetes (T1D) either use an insulin pump or multiple daily injections to take their insulin. Injection treatment requires using two types of insulin, and generally a total of four daily injections: One type of rapid-acting insulin, which is active for about four hours to cover … Read more
Maintaining blood sugar levels in range after meals is probably one of the toughest challenges that people with type 1 diabetes (T1D) have to face. Other than taking into account the countless, non-meal related factors that can impact blood sugar levels, they have to count the exact number of carbs they’re eating and anticipate how … Read more
Anyone with type 1 diabetes (T1D) will tell you that a cure or a technological breakthrough has been highly anticipated for years! Although no miracles are expected in the short term, ongoing technological advances for diabetes management still help to alleviate the burden of living of T1D. And while there is still room for improvement … Read more
Living with type 1 diabetes (T1D) requires constant attention and relentless efforts to manage blood sugar levels, administer insulin multiple times a day, count carbs, worry about hypo- and hyperglycemia and avoid long-term complications, with no break, 24/7, 365 days a year. So, people with T1D get understandably excited when they hear about new burden-reducing … Read more
First published: July 2021 / Updated: November 2022 Approved in the United States as of November 17th, 2022, Tzield (Teplizumab) injection is the first drug to prevent and delay the onset of type 1 diabetes (T1D) in people at high risk of developing it in the short term. Teplizumab is currently in clinical trials in … Read more
In 2021, type 1 diabetes (T1D) cases around the world were estimated at 8.7 million. According to estimates by the global Type 1 Diabetes Index (T1D Index) that were recently published in The Lancet Diabetes and Endocrinology scientific journal, that number could double by 2040. The article also provides details on the average age of … Read more
How many people are living with type 1 diabetes (T1D) in the world? What impact does this condition have on life expectancy? Which countries are most affected? There is little data specific to T1D on a global scale. In fact, although the profile of people affected, the causes and the treatments are very different from one … Read more
